PATIENT PACKAGE INSERT IN ACCORDANCE WITH
THE PHARMACISTS' REGULATIONS (PREPARATIONS) - 1986
The dispensing of this medicine requires a physician's prescription
Read this package insert carefully in its entirety before using this medicine
and every time this medicine is being prescribed for you,
as it may contain newer information
It is recommended to read this leaflet with one of your relatives

VERRUMAL
SOLUTION

Composition:
Active ingredients:
Each 100 g contains:
5-Fluorouracil 0.5 g
Salicylic acid 10.0 g

Inactive ingredients:
Ethyl acetate, Ethanol, Dimethyl sulfoxide, Poly (butyl methacrylate - co-methyl methacrylate) (80:20), Pyroxyline.

Therapeutic group: Wart and anti-corn preparations.

Therapeutic activity:
For the treatment of viral warts (verrucae).

When should the preparation not be used?

Do not use this medicine if you are pregnant, if pregnancy can not be excluded or if you are breastfeeding.
Do not use this medicine if you are sensitive to any of its ingredients or to salicylates.
Do not use in patients with DPD enzyme deficiency syndrome.
Do not use this medicine concomitantly or 4 weeks before or after the use of brivudine, sorivudine and their analogues (antiviral drugs).
Do not use in patients with renal insufficiency.
Do not use in Infants.

Do not use this medicine without consulting a physician before starting treatment:
If you are suffering or have suffered in the past from impaired function of the vascular system, sensory disturbances (e.g. patients with diabetes).

How will this medicine affect your daily life?
Verrumal has no influence on the ability to drive.

Drug interactions:
If you are taking another drug concomitantly or if you have just finished treatment with another medicine, inform the attending physician in order to prevent hazards or lack of efficacy arising from drug interactions. This is especially important for drugs belonging to the following groups: other skin preparations, methotrexate, sulphonylurea, phenytoin.

Please inform your physician if you are taking any medicine containing fluorouracil, brivudine, sorivudine or their analogues. Do not use this medicine 4 weeks after the use of fluorouracil, brivudine, sorivudine and their analogues (antiviral drugs). Before starting treatment with fluoropyrimidines your physician will perform all the necessary tests for determination of DPD enzyme activity (if relevant).

Side effects:
In addition to the desired effect, adverse reactions may occur during treatment with this medicine, for example: a burning sensation, particularly during application, as well as whitened skin around the treated wart, itching and small blisters even outside the area of contact.

Side effects that require special attention:
Allergic reaction or skin inflammation (red skin), refer to the physician immediately.
In the event that you experience side effects not mentioned in this leaflet, or if there is a change in your general health, consult your physician immediately.
If you had experienced any of the side effects listed above, or any other side effect please contact us: Neopharm Ltd., tel: 03-9373753, email: drugsafety@neopharmisrael.com

Dosage:
Dosage is according to physician's instructions only.

Recommended dosage unless otherwise prescribed by your physician:
Apply Verrumal solution twice or three times a day, on each wart.
This medicine is not intended for use in infants.

Attention!
This medicine is intended for external use only.
Avoid contact with eyes and mucous membranes.
The treated area should not exceed 25 cm^2.
Care should be taken while applying the Verrumal solution. Avoid contact of Verrumal solution with textiles or acrylics (e.g. acrylic baths).

Directions for use:
Wash the affected area with soap and water and dry before treatment. Apply the Verrumal solution onto the wart only, avoid contact with the healthy skin surrounding the wart. You may cover the surrounding skin with a protective fatty ointment. It is advisable to wipe off the brush on the bottle neck before application. Small warts may be treated with a toothpick instead of a brush, in order to ensure accurate application.
The average duration of treatment is 6 weeks.
After the treatment is proven successful, continue treatment for an additional 7 days.
If areas of skin with a thin epidermis are afflicted by warts, the solution should be applied less frequently since it may result in the formation of scars.
Close the bottle tightly immediately after the use since the contents dries up quickly if the bottle remains open.

How can you contribute to the success of the treatment?

Complete the full course of treatment as instructed by the physician.

Avoid poisoning!
This medicine, and all other medicines, must be stored in a safe place out of the reach of children and/or infants, to avoid poisoning. If you have taken an overdose, or if a child has accidentally swallowed the medicine, proceed immediately to a hospital emergency room and bring the package of the medicine with you.
Do not induce vomiting unless explicitly instructed to do so by a physician!
This medicine has been prescribed for the treatment of your ailment; in another patient it may cause harm.
Do not give this medicine to your relatives, neighbours or acquaintances.
Do not take medicines in the dark! Check the label and the dose each time you take your medicine. Wear glasses if you need them.

Storage:
Store in a tightly closed container.
Do not store at temperatures below 10°C or above 25°C.
Once the bottle was opened, this medicine should not be used for longer than 6 months.
Caution! Inflammable fluid! Keep away from fire.
Even if kept in their original container and stored as recommended, medicines can be kept for a limited period only. Please note the expiry date of the medicine! In case of doubt, consult the pharmacist who dispensed the medicine to you. Do not store different medications in the same package.

License number: 01034 24061 00

Manufacturer: Almirall Hermal GmbH, Germany.
License holder: Neopharm Ltd., P.O.Box 7063, Petach-Tiqva 49170.

The format of this leaflet has been defined by the Ministry of Health; its content has been checked and approved October 2010.

NEOPHARM